Granulocytic sarcoma’s extramedullary site contains of myeloid blasts and/or immature myeloid cells leads to an event associated with myeloid leukemia. In many cases, 47% of the patients of granulocytic sarcoma were oftenly misdiagnosed who’s having malignant lymphoma. It becomes a diagnostic challenge especially when lymphnode becomes an extramedullary with remote co-incidence as well as in the absence of cited hematological disorder. Pathologist are often mislead particularly without a clear diagnosis of acute myeloid leukemia in patients.
However the diagnosis difficulties would be overcome with advances in diagnostic techniques and can be made more reliable result. The use of flow cytometry in diagnosis of granulocytic sarcoma has redifened its utility with accuracy. Another technique immunohistochemistry staining using antibodies against CD33 and CD117 would be the mainstay of diagnosis. The use of CD68, CD43, and CD20, monoclonal antibodies against myeloperoxidase, differentiates it from lymphoma and to accurately diagnose granulocytic sarcoma via immunohistochemistry. The diagnosis of granulocytic sarcomas can be made more reliable.
In different AML subgroups, granulocytic sarcoma makes very difficult to study its' impact as because of its rare phenomena. The chemotherapy treatment to AML patient with granulocytic sarcoma has substantiated improvement compare to the AML patient with out having the granulocytic sarcoma. The various literatures suggest that patients with isolated granulocytic sarcoma may have a better prognosis compared with AML patients without granulocytic sarcoma. The diagnosis of granulocytic sarcoma is variably depends on clinicopathologic diagnosis with a malignant lymphoma because of its different mass presentation.